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Migrated t lymphocytes into 
malignant pleural effusions: an 
indicator of good prognosis in lung 
adenocarcinoma patients
Juan C. Nieto1, Carlos Zamora1, José M. porcel2, Maria Mulet1, Virginia pajares3, 
Ana M. Muñoz-Fernandez3, Nuria Calvo4, Iñigo espinosa5, Mónica pascual-García5, 
silvia Bielsa2 & silvia Vidal  1
The presence of leukocyte subpopulations in malignant pleural effusions (MPEs) can have a different 
impact on tumor cell proliferation and vascular leakiness, their analysis can help to understand the 
metastatic microenvironment. We analyzed the relationship between the leukocyte subpopulation 
counts per ml of pleural fluid and the tumor cell count, molecular phenotype of lung adenocarcinoma 
( LAC), time from cancer diagnosis and previous oncologic therapy. We also evaluated the leukocyte 
composition of MPEs as a biomarker of prognosis. We determined CD4+ T, CD8+ T and CD20+ B cells, 
monocytes and neutrophils per ml in pleural effusions of 22 LAC and 10 heart failure (HF) patients by 
flow cytometry. Tumor cells were identified by morphology and CD326 expression. IFNγ, IL-10 and IL-
17, and chemokines were determined by ELISAs and migratory response to pleural fluids by transwell 
assays. MPEs from LAC patients had more CD8+ T lymphocytes and a tendency to more CD4+ t and 
CD20+ B lymphocytes than HF-related fluids. However, no correlation was found between lymphocytes 
and tumor cells. In those Mpes which were detected >1 month from LAC diagnosis, there was a 
negative correlation between pleural tumor cells and CD8+ T lymphocytes. CXCL10 was responsible 
for the attraction of CD20+ B, CD4+ T and CD8+ T lymphocytes in malignant fluids. Concentrations 
of IL-17 were higher in MPEs than in HF-related effusions. Survival after MPE diagnosis correlated 
positively with CD4+ T and CD8+ T lymphocytes, but negatively with neutrophils and IL-17 levels. In 
conclusion, lymphocyte enrichment in MPEs from LAC patients is mostly due to local migration and 
increases patient survival.
The cellular content of pleural effusions differs depending on the etiology of the disease. Parapneumonic and 
malignant pleural effusions (MPE) are the most common causes of exudates, whereas heart failure (HF) causes 
the majority of transudates1. More than half of MPEs are due to metastases from lung and breast carcinomas2.
In patients with lung cancer, the presence of MPE contraindicates surgery and is predictive of poor prognosis, 
with a median survival of 5.5 months3. Pleural fluid formation in MPEs was traditionally considered to be the 
result of the tumorigenic obstruction of lymphatic vessels4. However, mouse models have revealed that MPE 
is the net product of an impaired pleural lymphatic drainage and increased fluid production due to extravasa-
tion from hyperpermeable pleural and/or tumor vessels induced by mediators that are released from tumor and 
tumor-recruited cells5. Autopsy studies have indicated that tumor cells metastasize to the pleural cavity mainly 
through the bloodstream6. Tumor-derived mediators directly stimulate inflammatory cell influx to the pleura and 
initiate vascular changes7,8. In the pleura, attracted leukocytes accumulate locally and have an impact on pleural 
tumor cell proliferation and vascular leakiness9,10.
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The management of MPEs remains palliative due to its dismal prognosis11. Prognosis depends on several 
factors such as lactate dehydrogenase in pleural fluid, Easter Cooperative Oncology Group (ECOG) performance 
score, blood neutrophil-to-lymphocyte ratio, and primary tumor; all of which integrate to form a validated prog-
nostic score in MPEs known as the LENT scoring system12. For the generation of the LENT score, the pres-
ence and type of pleural fluid leukocytes was not evaluated; an analysis which could be potentially valuable. 
Different types of comparisons have been established to analyze the leukocyte composition. When compared 
with peripheral blood, MPEs have more Th17, Th9 and Th1 lymphocytes13,14 and higher levels of IL-1 IL6, IL-17, 
and TGFβ15,16. Other authors described a bias towards a Th2 dominant state in MPEs from different primary neo-
plasms17. When compared with parapneumonic effusions, MPEs contain more lymphocytes, Tregs (regulatory 
T-cells), CD3+ and CD3 + CD25+ cells and less Th1716. Levels of IFN, IL-17, IL-16, and CCL20 were lower, but 
those of FoxP3, IL-10, TGFβ, and CCL17 were higher in MPEs than in tuberculous pleural effusions16. In fact, 
an elevated Treg/Th17 ratio in the MPEs of lung cancer patients is predictive of poor prognosis17. Divergences 
of these comparisons may be ascribed to variations in measurement techniques, sample preparations, failure to 
include control samples or methodological limitations18. Despite fluid cytology being a well-established diag-
nostic test for MPEs, its yield depends on sample preparation and cytologist experience and is insufficient for a 
detailed research analysis of leukocyte subsets19.
There is limited knowledge about the function of the leukocytes of MPEs. Macrophages from MPEs have 
a reduced cytotoxic activity and can inhibit tumor cell apoptosis20. Some reports have shown that T cell sub-
sets are involved in sculping the pleural microenvironment that regulates intra-pleural tumor dissemination and 
pleural fluid accumulation9. In particular, CD4+ T lymphocytes contribute to immune evasion and facilitate 
tumor growth21,22, whereas CD8+ T lymphocytes have a defective cytotoxic potential23,24. In addition, abundant 
cytokines with immune-inhibitory properties have been described in pleural cavities affected by malignancy25,26.
Our main objective was to determine the lymphocyte subpopulation composition in the MPE of patients with 
lung adenocarcinoma (LAC). Since pleural effusions have cells in suspension, we were able to apply flow cytome-
try with multiple antibodies against specific markers to determine the cells per ml of each subpopulation. As con-
trols, we included patients with effusions secondary to HF because they have a non-pathological representation of 
the local leukocyte populations27. To decipher the cause of MPE composition, we studied the association of leuko-
cyte count per ml with the number of tumor cells and the clinical characteristics of the primary tumor (mutations, 
years of evolution, time from diagnosis, previous therapy). We also prospectively analyzed whether the leukocyte 
composition of this metastasic environment could be used as a surrogate biomarker for the prediction of survival 
in LAC patients. Overall, our findings provide new insights into the pathophysiological mechanisms of pleural 
metastases from lung cancer.
Material and Methods
patients and sample collection. We analyzed 22 MPEs secondary to LAC and 10 benign effusions due to 
HF from patients who were attended at the Hospital Arnau de Vilanova (Lleida) and Hospital de la Santa Creu i 
Sant Pau (Barcelona). Samples were collected by thoracentesis and 10 U/ml of heparin were added to each sample. 
Diagnosis of MPE was based on positive cyto-histological studies. The study was approved by the Institutional 
Ethics Committee of the Hospital de la Santa Creu i Sant Pau. Patients signed an informed consent and samples 
were anonymized. Table 1 summarizes the patients’ clinical and pathological features, and the biochemistry of 
pleural fluids.
Staining and flow cytometry analysis of pleural fluid cells. Ten ml of pleural fluid were passed 
through a 40 µm filter and the cellular pellet was spun down. Then, red blood cells (RBC) were lysed using a 
soft RBC lysing solution (BioLegend, San Diego, CA). Cellular viability was then assessed using violet fluo-
rescent reactive dye (Life Technologies, Carlsbad, CA). We included only samples with >95% cellular viabil-
ity. The total number of nucleated cells was quantified in a MACSQuant cytometer (Miltenyi Biotec, Bergisch 
Gladbach, Germany). Cells were first incubated with FcR blocking and adjusted to 10 × 106 cells/ml. One mil-
lion cells were then stained with three panels of antibodies for 20 min at 4 °C. Panel A included anti-CD45-PE, 
CD20-FITC (Immunotools, Friesoythe, Germany), CD3-PECy5 and CD4-PECy7 or CD8-PECy7 (BioLegend). 
Panel B included anti-CD45-Vioblue (Miltenyi Biotec), CD14-APC, CD3-PECy5, CD16-FITC, and CD56-PE 
(Immunotools). Panel C included anti-CD45-Vioblue and CD326 (EpCAM)-PECy7 (Miltenyi Biotec). Cells were 
finally washed with PBS +1% BSA and resuspended in 300 µl for cytometry acquisition. For the analysis, aggre-
gates, debris, and nonviable cells were excluded from our analysis based on forward (FSC) and side scatter (SSC). 
Leukocyte populations were identified based on the analysis of CD45+ cell gate. The least complex and small-
est leukocytes corresponded to lymphocytes, and T and B subsets were identified as CD3+ and CD20+ cells, 
respectively. Inside the lymphocyte gate, NK cells were identified as CD3-CD16 + CD56 + cells, CD4+ T cells 
were analyzed as CD20− CD3 + CD4+, and CD8+ T cells as CD20− CD3 + CD8+. Monocytes and neutrophils 
were identified as CD14 + CD45+ and CD16 + CD14-CD45+ cells, respectively. Tumor cells were identified as 
CD45-CD326+ cells. The frequency (%) and cell number/ml were calculated for each cellular subset using the 
MACSQuantify software.
Migration assay to malignant pleural fluid and analysis of migrated peripheral blood lympho-
cytes from healthy donors. Whole blood was lysed with RBC lysing solution (BioLegend). Cells were 
washed and the cell count was performed by MACSQuant cytometer. Cells were resuspended in RPMI 1640 with 
10% fetal calf serum (Biological Industries, Kibbutz Beit Haemek, Israel), 2 mM glutamine, 100 U/ml penicil-
lin, and 100 mg/ml streptomycin (Biowhittaker, Verviers, Belgium) at 2 × 106 cells/ml. In 24 plate-wells, 500 μl 
of RPMI 1640 with 10% fetal calf serum or 0.22 μm filtered medium RPMI supplemented with 10% of pleural 
fluid from LAC was added to the wells. 3 × 105 cells were added in 3 μm pore-size filters (Millipore Corporation, 
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Billerica, MA) and incubated for 4 h at 37ΊC. After culture, healthy donor cells that migrated towards the medium 
or pleural fluids were collected from the wells, washed with PBS and stained with anti-CD3-PECy5, CD4-PECy7 
(BioLegend) and CD20-FITC (Immunotools) monoclonal antibodies for 20 min. Cells were washed and resus-
pended in 300 μl of PBS to be acquired by flow cytometry. To analyze the migration fold of cells towards the 
pleural fluids, we calculated the relative cell migration that is the ratio between the absolute numbers of CD4+ T, 
CD8+ T cells and CD20+ B cells that migrate to the medium supplemented with pleural fluid and the absolute 
cell numbers of each respective subset that migrate to the medium.
Proliferation assay of T cells from pleural effusions. To determine proliferation, 107 T lymphocytes 
from LAC and HF fluids were labeled with 7 μM of 5(6)-carboxyfluorescein diacetate succinimidylester (CFSE) 
(Sigma, S. Louis, Missouri) for 15 minutes at 37 °C. The cells were then washed with pre-warmed medium, resus-
pended with complete medium at 5 × 106 cells/ml and incubated with complete medium or with anti-CD3, 
anti-CD28, and anti-CD2 T cell activation/expansion kit for 72 hours according to the manufacturer’s instruc-
tions (Miltenyi Biotec). After culturing, pleural fluid cells were collected and stained with anti-CD3-PECy7, 
CD8-PErCP (BioLegend) and CD45-Vioblue and violet fluorescent reactive dye (Miltenyi Biotec). The cells were 
rewashed and resuspended in 300 μl of PBS.
Determination of cytokine and chemokine concentrations in Mpes. Cell-free pleural fluids were 
obtained by centrifugation and then kept at −80 °C until use. IL-10 (Immunotools), IL-17 (Peprotech, London 
UK), IFNγ (BD Biosciences), MCP-1, CXCL4 and CXCL10 levels were determined using specific ELISA kits 
(Peprotech) according to the manufacturer’s instructions. All cytokines and chemokines were quantified with 
standard curves provided by the corresponding ELISA kit. The limits of detection were: 2 pg/ml for IL-10 and 
IL-17, and 30 pg/ml for IFNγ, CXCL10, CXCL4 and MCP-1.
statistical analysis. Statistical analyses were performed using Graph Pad Prism 7 software. Variables were 
reported as median (interquartile range –IQR-). The Kolmogorov-Smirnov test was applied to test for a normal 
distribution. Comparisons between groups were evaluated with the Mann Whitney test. Correlation analyses 
were carried out with the Spearman’s correlation test. P values < 0.05 were considered significant.
LAC HF P value
Patients, n 22 10
Age, yearsa 64(60–74.73) 85(82.3–87.13) n.s.
Male/femaleb 15/7 7/3 n.s.
Lactate Dehydrogenase (U/L) 614(410–927) 184(132–224) <0.001
Total Protein (g/dL) 4.5(4.1–5.47) 2.9(2.4–3.4) <0.001
Glucose (mg/dL) 104(85.2–169) 130(118–182) n.s.
C-reactive protein (mg/L) 9.8(6.4–15.65) 5(2.2–14.5) n.s.
Adenosine Deaminase (U/L) 9.3(2.9–22.9) 4.3(2.75–104) n.s.
pH 7.4(7.34–7.44) 7.42(7.43–7.54) n.s.
Mean (±SD) time from diagnosis, days 235 ± 444
Mean (±SD) survival time from 
diagnosis, days 306 ± 218
EGFR mutations 4/21
ALK translocations 1/12
Treatment
Chemotherapy 6/22
EGFR inhibitors 1/22
Her2 inhibitors 1/22
Immunotherapy 3/22
Radiotherapy 1/22
Surgery 1/22
Relative pleural fluid composition (%)a
CD20+ B lymphocytes /lymphocytes 5.81(4.08–11) 3.71(0.75–6.01) 0.04
CD4+ T lymphocytes/lymphocytes 63(50.21–67.55) 63(52.08–73.78) n.s.
CD8+ T lymphocytes/lymphocytes 23.52(17.86–29.97) 18.5(12.11–24.96) n.s.
NK cells/lymphocytes 0.8(0.56–2.25) 2.94(1.3–9.51) 0.006
CD16 + CD14- neutrophils/leukocytes 0.78(0.26–2.8) 1.77(0.8–6.81) n.s.
CD14+ monocytes/leukocytes 10.2(1.75–27.7) 23.9(10.71–42.26) n.s.
Table 1. Clinical characteristics of LAC and HF patients, and relative leukocyte composition of their pleural 
fluids. ALK: anaplastic lymphoma kinase; EGFR: epidermal growth factor receptor; HF: heart failure; LAC: lung 
adenocarcinoma; MPE: malignant pleural effusion; NK: natural killer; n.s.: non-significant. aComparison by 
Mann Whitney test. bComparison by Fisher test.
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ethical approval. All procedures performed in studies involving human participants were in accordance 
with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki 
declaration and its later amendments or comparable ethical standards.
Results
Cellular composition of malignant and non-malignant pleural effusions. There were more CD45+ 
cells per ml in MPEs from LAC than in pleural fluids from HF (Fig. 1). MPEs had more CD8+ T lymphocytes 
and a tendency to have more CD4+ T and B lymphocytes per ml than pleural fluids from HF patients. No dif-
ferences in the NK cells, macrophages and neutrophils per ml were observed between LAC and HF effusions 
(NK: 2.65(1.30–6.33) × 103 cells/ml for LAC vs 5.58(1.06–13.55) × 103 cells/ml for HF; macrophages: 34.85(3.77–
64.47) × 103 cells/ml for LAC vs 16.09(7.31–46.82) × 103 cells/ml for HF; neutrophils: 1.67(0.84–8.88) × 103 cells/
ml for LAC vs 1.28(0.61–9.94) × 103 cells/ml for HF). The percentages of NK cells and CD20+ B lymphocytes, but 
not CD4+ T and CD8+ T lymphocytes, were different between LAC and HF pleural effusions (Table 1).
Relationship between lymphocytes and tumor cells in malignant pleural effusions from lung 
adenocarcinoma. A strong correlation between CD4+ T, CD8+ T and CD20+ B lymphocytes per ml was 
observed in MPEs from LAC (r = 0.731 for CD8+ vs CD4+ T, p < 0.001; r = 0.859 for CD20+ B vs CD4+ T, 
p < 0.001; and r = 0.658 for CD20+ B vs CD8+ T, p < 0.001) (Fig. 2). We next evaluated the correlation between 
the lymphocytes per ml of each subpopulation and the number of EpCAM+ CD45− tumor cells per ml. No 
correlation was observed between CD4+ T, CD8+ T or CD20+ B cells and tumor cells. However, selecting LAC 
patients that developed a MPE >1 month from the time of lung cancer diagnosis, a negative correlation between 
tumor cells and CD8+ T lymphocytes was observed (r = −0.964, p = 0.002). We did not find differences in any 
subpopulation of lymphocytes per ml between patients that had received treatment previous to the MPE devel-
opment (n = 11) and those who did not (n = 11) (CD4+: 101.09(37.84–119.81) × 103 cells/ml vs 102.96(43.09–
202.55) × 103 cells/ml; CD8+ T: 34.62(9.33–60.95) × 103 cells/ml vs 36.20(24.45–52.03) × 103 cells/ml; CD20+ 
B: 8.55(3.19–13.71) × 103 cells/ml vs 7.65(2.13–14.88) × 103 cells/ml, respectively). No differences in lymphocytes 
per ml were observed in patients with (n = 4) and without (n = 17) EGFR mutations (CD4+ T: 85.35(16.27–
330.46) × 103 cells/ml vs 101.09(40.46–130.42) × 103 cells/ml; CD8+ T: 47.78(26.99–162.17) × 103 cells/ml vs 
34.23(13.81–51.68) × 103 cells/ml; CD20+ B: 9.90(2.65–126.82) × 103 cells/ml vs 7.37(2.92–13.97) × 103 cells/
ml, respectively). However, we found more EpCAM + CD45- tumor cells cells/ml in patients without previous 
oncologic treatment than in those that had received it (7.47(1.94–21.23) × 103 cells/ml vs 1.26(0.05–3.22) × 103 
cells/ml, p = 0.02; respectively).
Figure 1. Leukocytes and lymphocyte subpopulations in malignant and non-malignant pleural effusions. Cells 
from MPEs of lung adenocarcinoma (LAC) and heart failure (HF) were stained with anti-CD3, CD4, CD14, 
CD16, CD20 and CD45 monoclonal antibodies to be analyzed by flow cytometry. Data are presented as mean. 
CD4+ cells/ml and CD20+ cells/ml in LAC and HF tended to be different (p = 0.04 and p = 0.06 respectively). 
Statistical analysis was performed using a non-parametric Mann-Whitney test. p < 0.05 was considered 
statistically significant. *p < 0.05.
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Migration of lymphocytes to malignant pleural fluids and its association with CXCL10 concen-
tration. It is unlikely that the higher counts of lymphocytes per ml in MPEs as compared with non-MPEs 
could be explained by an increased cell proliferation in the former because we observed that CD4+ T and CD8+ 
Figure 2. Correlation between lymphocyte populations and tumor cells in malignant pleural effusions from 
lung cancer. Cells from MPEs of LAC patients were stained with anti-CD3, CD4, CD20, CD45 and EpCAM 
(CD326) monoclonal antibodies to be analyzed by flow cytometry. Tumor cells were identified as CD45- CD326 
(EpCAM)+ cells. Correlations between CD4+ T and CD8+ T, CD4+ T and CD20+ T, and CD8+ T and 
CD20+ B lymphocytes cells/ml and between tumor cells/ml and CD4+ T, CD8+ T and CD20+ B lymphocytes 
cells/ml were analyzed by Spearman’s correlation. Black circles correspond to LAC patients diagnosed with 
cancer >1 month before of MPE formation. Statistically significant correlations (p < 0.05) are shown.
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T lymphocytes from both MPEs and non-MPEs had comparable spontaneous proliferation (data not shown). 
We then studied the capability of MPEs for attracting peripheral blood lymphocytes. It was observed that MPEs, 
attracted CD20+ B, CD4+ T and CD8+ T cells (relative cell migration towards MPE in fold change compared 
to control medium: CD20+ B: 2.85(1.65–5.12); CD8+ T: 2.35(2.05–3.07); CD4+ T: 1.95(1.47–2.5)) (Fig. 3). The 
relative cell migration of each lymphocyte subset to malignant pleural fluids was comparable to the increment of 
each subset in MPEs (increment of LAC cells in fold change compared to HF cells: CD20+ B: 1.51(0.57–2.68); 
CD8+ T: 1.73(0.9–2.69); CD4+ T: 1.31(0.53–2). In fact, relative cell migration towards malignant fluids and the 
increment of T lymphocytes per ml in MPEs strongly correlated (r = 0.719, p = 0.02). We next evaluated whether 
CXCL10 and MCP-1, two chemokines involved in T lymphocyte migration, could be playing a role in these 
findings. There was a correlation between the levels of total protein and CXCL10 (R = 0.717, p = 0.02). There 
was a correlation between CXCL10 levels (pg/ml) in MPEs and the CD4+ T and CD8+ T lymphocytes migrated 
to MPE (r = 0.614, p = 0.05; r = 0.46, p = 0.17 and r = 0.709, p = 0.02, respectively). In addition, the levels of 
CXCL10 in malignant fluids also correlated with the CD4+ T and CD8+ T cell count per ml (r = 0.562, p = 0.015 
and r = 0.591, p = 0.009, respectively). No correlation was found between pleural fluid MCP-1 and CXCL4 levels 
and relative cell migration to malignant fluids and lymphocytes per ml in MPEs (data not shown).
Levels of T-related cytokines in pleural fluids and their relationships with T lymphocyte pop-
ulations. We next compared the T-cell derived cytokines (IL-10, IFNγ, and IL-17) in malignant and benign 
pleural effusions. In the former, concentrations of IL-10 tended to be lower and those of IL-17 significantly higher 
than in the latter (Fig. 4). IFNγ levels in LAC and HF pleural fluids were comparable. There was a significant 
correlation between IFNγ levels (but not IL-10 and IL-17 levels) and the CD4+ T lymphocytes per ml in MPEs. 
No correlation was found between the levels of cytokines and the CD8+ lymphocytes per ml (data not shown).
Association between leukocytes and cytokine levels in Mpe and survival after Mpe diagno-
sis. We found that CD4+ T and CD8+ T lymphocytes per ml positively correlated with the days of survival 
after MPE diagnosis (r = 0.578, p = 0.009 and r = 0.652, p = 0.002, respectively) (Fig. 5). CD20+ B lymphocytes 
also tended to correlate with survival (r = 0.454, p = 0.051, data not shown). Neutrophils per ml and the levels of 
IL-17, but not of IL-10 and IFNγ, negatively correlated with survival from MPE diagnosis (r = −0.525, p = 0.03, 
and r = −0.593, p = 0.009, respectively). In fact, the levels of IL-17 and neutrophils per ml were positively corre-
lated (r = 0.485, p = 0.03; data not shown).
Discussion
Lymphocytes are more abundant in MPEs from LAC than in HF-related effusions. There was a correlation 
between the absolute counts of CD4+ T, CD8+ T and CD20+ B lymphocytes per ml in MPEs. This finding 
suggests that the increase of each subset originated from a common mechanism. Using an in vitro experiment 
we showed that each subpopulation of lymphocytes was attracted to malignant fluids, and CXCL10 was a crucial 
chemokine involved in this phenomenon. The survival of LAC patients was positively correlated with the pres-
ence of CD4+ T and CD8+ T lymphocytes but negatively correlated with the presence of neutrophils and the 
levels of IL-17 in the pleural fluid.
It was shown that there were more lymphocytes, but not monocytes or neutrophils, in MPE than in benign 
fluids. Also, lymphocytes were mostly CD4+ and the ratio CD4+/CD8+ was similar in both malignant and 
non-malignant pleural effusions28,29. Our findings of lymphocytes being the predominant cell population in 
MPEs are comparable with some previous studies30. However, other reports analyzing the percentages instead 
of cell counts have suggested a different conclusion. For instance, Leiser et al. reported a lower accumulation of 
CD8+ T cells but a higher percentage of CD14+, dendritic and mesothelial cells in MPEs compared to benign 
pleural effusions. In contrast to our study, benign pleural effusions were represented by inflammatory diseases 
where the inflammatory mediators could be different17 Scherpereel et al. also reported that pleural fluids from 
donors with essential hyperhidrosis, considered as controls because of the absence of thoracic disease, contained 
mainly CD8+ T cells, while MPEs included mostly CD4+ T lymphocytes24. There are two major differences that 
could explain the discrepancy between control group findings when either heart failure or essential hyperhidrosis 
is used. One difference is that effusions from hyperhidrosis were obtained by pleural lavage (injection and imme-
diate aspiration of 150 mL of prewarmed saline into the pleural space) whereas heart failure effusions, as MPE, 
were obtained by direct thoracentesis. Another possible difference is that the previous therapies in heart failure 
and hyperhidrosis could have distinctively altered the leukocyte repertoire of these effusions. Prado-Garcia et al. 
showed that in MPEs from primary lung cancer, the percentage of CD8+ T cells, in particular, the terminally dif-
ferentiated subset, was reduced compared to non-malignant effusions because they underwent antibody-induced 
cell death31. Two possible differences between these reports and our findings could be that they compared lym-
phocyte percentages and that malignant fluids might have been collected at a different time from diagnosis. This 
last aspect could be relevant because the predominant leukocyte subpopulation could depend on the phase of 
the pleural metastasis32. The latter, however, seems unlikely because we were not able to correlate the time from 
diagnosis to lymphocyte count per ml in our cohort of patients. To conclusively evaluate the possibility of changes 
in the predominant cell population, the collection of consecutive samples from the same patient will be of interest 
in future studies.
Although an increased influx of circulating monocytes and macrophage differentiation is expected during an 
inflammatory response associated with cancer, macrophage counts did not increase in MPEs and we, similarly 
to Risberg et al., could not establish any relationship between the presence of macrophages and CD326+ tumor 
cells33. Immunophenotyping of macrophage subpopulations may further reveal details of particular macrophages 
and their relationship with tumor cells.
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Figure 3. Association between migration of lymphocytes toward malignant pleural fluids and number of 
lymphocytes in malignant pleural effusions. Lysed whole blood cells from healthy donors (3 × 105 cells) were 
added to 3 μm insert transwells. Under insert, culture medium with 10% of FCS or medium with 10% of MP 
fluid was added to the well. After 4 h, cells were collected from the well and stained with anti-CD3 and CD4. (A) 
Migration folds of CD20+ B, CD8+ T, and CD4+ T lymphocytes in a medium with 10% MP fluid vs medium 
with 10% FCS are shown. (B) Increments of CD20+ B, CD8+ T and CD4+ T lymphocytes in MPE from LAC 
vs HF are shown. Correlation of fold of migrated T lymphocytes with (C) T lymphocytes cells per ml in MPE 
and with (D) CXCL10 levels (pg/ml) in MP fluids. Correlation of CXCL10 levels with the fold of (E) migrated 
CD4+ T and (F) CD8+ T lymphocytes and (G) CD4+ T lymphocytes and (H) CD8+ T lymphocytes per ml in 
MPE. We used Spearman’s correlation. Statistically significant correlations (p < 0.05) are shown.
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We agree with other reports in that neutrophils constitute <25% of the cell population in MPEs34. However, 
we found an increase in neutrophils in those MPEs with more tumor cells, suggesting their recruitment from 
circulating blood through the local release of chemotactic factors. Consistently, some reports have shown a sig-
nificant positive correlation between pleural IL-8 concentrations and neutrophil counts35.
Our findings suggest that the increased number of lymphocytes in MPE were due to migration rather than 
proliferation, which is in agreement with reports showing a defective proliferative capacity of MPE lymphocytes. 
Yang et al. have previously demonstrated that CD4+ T lymphocytes frequently accumulate in metastatic MPEs16. 
However, we did not find a positive correlation between the number of tumor cells and lymphocytes.
Migration of leukocytes has been a crucial mechanism in experimental MPE because CCL2 and anti-CCL12 
blockades were able to inhibit MPE development in mouse models36. Lymphocyte migration can also be sup-
ported by the higher levels of osteopontin, SSP1, and VEGF in exudates, which promote vascular hyperper-
meability and correlate with pleural inflammation5. In our cohort of patients, we have found that lymphocytes 
migrated towards malignant fluids in the same proportion that they were present in pleural fluids. The in vitro 
migration of T lymphocytes and the lymphocyte count per ml in MPEs were positively correlated with the pleural 
concentration of CXCL10. Although we cannot rule out the involvement of other CXCR3 ligands, our findings 
suggest a relevant role for CXCL10, linked to the attraction of Th1, in the accumulation of lymphocytes in MPEs. 
Although we did not find a significant increase of IFNγ in malignant fluids, its consumption cannot be ruled out 
in this setting. The complex kinetics of cytokines and lymphocytes require further studies about the production of 
IFNγ and the role of other chemokines at different times from the diagnosis of LAC and after therapy.
A higher concentration of IL-17 in MPEs than in HF-related effusions was found, and the IL-17 levels were 
inversely correlated with survival. It has already been reported that there are higher IL-17 levels in MPEs than in 
non-malignant effusions, with values below 15 pg/ml being associated with longer overall survival37. The role of 
Th17, the main T cell subset that produces IL-17, in cancer is hardly conclusive. Controversially, Th17 cells have 
been found in both pro- and antitumorigenic processes38,39. The protumor function mediated by Th17 and IL-17 
has been demonstrated both in animal tumor models and patients with cancer40,41, and a higher ratio Treg/Th17 
was highly correlated to poor survival16. IL-17 can act as an angiogenic factor accelerating tumor growth and 
metastasis through neo-vascularisation. Th17 is also able to induce the secretion of inflammatory cytokines such 
as IL-8 and TNF which will attract neutrophils and destroy the niche of immunity42,43. On the other hand, Th17 
may contribute to protective tumor immunity via stimulating the production of Th1 chemokines CXCL9 and 
Figure 4. IL-10, IFNγ and IL-17 levels in MPE from LAC and pleural fluids from HF and the relationship of 
cytokines with T CD4+ lymphocytes per ml in MPE. Pleural fluids LAC and HF patients were filtered with 0.22 
μm. (A) OD levels of IL-10, IFNγ, and IL-17 determined by ELISA. IL-10 levels in LAC and HF tended to be 
different (p = 0.06). Mann-Whitney test was used for comparison between LAC and HF. Correlation of CD4+ 
cells/ml with OD of (B) IL-10, (C) IFNγ and (D) IL-17 was analyzed by Spearman’s correlation. p < 0.05 was 
considered statistically significant. *p < 0.05.
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CXCL10 to recruit effector cells to tumor tissues44 and to elicit the activation of tumor-specific CD8+ T cells45. 
The number of Th17 cells has been reported to be elevated in MPEs, a fact which predicted the improved survival 
of these patients. Ye et al. also showed that the number of Th17 was significantly increased in the MPEs of patients 
with prolonged survival, implying a beneficial role43. However, our findings are in accordance with the tradition-
ally reported role of Th1 cells and IFN as the major mediators of antitumor immunity.
Despite being focused on the immunological microenvironment of pleural metastasis, this study was limited 
to LAC patients. It is likely that MPEs from patients with other malignancies have other immunological patterns 
due to differences in time of diagnosis, evolution, therapy and tumor characteristics.
Using flow cytometry, we were able to establish a quantitative comparison of lymphocyte subpopulations 
between pleural effusions related to LAC and HF. It was found that migration has a central role in the predom-
inance of pleural fluid lymphocytes and that IL-17 levels and attracted neutrophils are indicative of poor prog-
nosis. These findings suggest that MPE cells are a convenient source to study the host-tumor interactions. Due 
to the inherent disseminated stage of MPE secondary to LAC, this could also be an excellent model to study the 
evasion mechanisms of tumors. Accurate characterization of tumor cells and tumor-associated leukocytes by flow 
cytometry may help to introduce an innovative diagnostic tool and open new prospects for cell therapy in MPEs. 
However, we cannot ignore that these pleural tumor cells are metastatic and that cells from the primary tumor 
could have a different phenotype and response.
Compliance with ethical standards. Research Involving Human Participants. We obtained signed 
informed consent.
Figure 5. Association of cytokines and leukocytes per ml in MPE with survival days from MPE formation. 
Correlation between survival days after MPE formation and cells per ml of (A) CD4+ T, (B) CD8+ T, (C) 
IL-17 and (D) neutrophils per ml was analyzed by Spearman’s correlation. p < 0.05 was considered statistically 
significant.
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